heat shock protein family A (Hsp70) member 9Genealiases: CRP40 · CSA · EVPLS · GRP-75 · GRP75 · HEL-S-124m
Q-omics provides the consensus-scored HSPA9 profile across patient tissues and cancer cell-line models. HSPA9 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, HSPA9 is differentially expressed in 15, with the highest sampling consensus in STAD. Additionally, HSPA9 protein abundance shows 21,582 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, STAD, and LSCC as cancer lineages where HSPA9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSPA9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSPA9 survival associations across molecular data types. HSPA9 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSPA9 RNA expression–survival associations across cancer types. High HSPA9 expression shows unfavorable associations in LUAD, UVM, HNSC and ESCA, but favorable associations in READ and KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for HSPA9 RNA expression.
This table summarizes HSPA9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HSPA9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSPA9 shows lower tumor expression in THCA and higher tumor expression in STAD, LUAD, COAD, LIHC and LUSC. The STAD box plot shows higher HSPA9 RNA expression in tumor versus normal tissue (log2 FC = +0.948, t-test p < 0.001).
This table shows molecular features associated with HSPA9 in patient tissues and cancer cell lines. In patient samples, HSPA9 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, HSPA9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
